All In Biotech

Drug Trial Radar · NCT06639256

Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors

An Open-label, Multiple-center, Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

258

Planned (sponsor's estimate)

Start

Oct 24, 2024

Primary completion

May 26, 2027

Study completion Oct 26, 2027

Sponsor

Sponsor type
Industry
First posted
Oct 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, open-label, phase 1/2 study to evaluate the safety, efficacy, and pharmacokinetic (PK)/pharmacodynamic (PD) characteristics of HY07121 in participants with advanced solid tumors.

Conditions

  • Safety
  • Tolerability
  • Efficacy

Interventions

  • Test Product HY07121Drug

    HY07121 should be administered intravenously at recommended dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Escalation (Part One): Incidence and Nature of Dose-Limiting Toxicity (DLT)Time frame: 21 days during the first 3-week cycle
  2. Dose Escalation (Part One): Percentage of participants experiencing treatment-emergent adverse events (TEAEs)Time frame: Up to 2 years
  3. Dose Escalation (Part One): Percentage of participants experiencing Adverse Event (AE) related dose interruptions, dose delays, and dose intensityTime frame: Up to 2 years
  4. Dose Expansion (Part Two): Objective Response Rate (ORR)Time frame: Up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital of Shandong First Medical University

    Jinan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.